COVID-19 presenting as acute pancreatitis

Aloysius, Mark M.; Thatti, A.; Gupta, Anjalika; Sharma, Nishant; Bansal, Pardeep; Goyal, Hemant

doi:10.1016/j.pan.2020.05.003

Cited by 181 publications

(221 citation statements)

References 6 publications

(6 reference statements)

Supporting

Mentioning

193

Contrasting

Unclassified

Order By: Relevance

“…Besides various autoinflammatory/autoimmune conditions ( Rodríguez et al, 2020 ), a couple of recent observations have also evinced potential diabetogenic effect of COVID-19 ( Aloysius et al, 2020 ; Ren et al, 2020 ; Rubino et al, 2020 ). Attributable to the tropism of SARS-CoV-2 for the pancreatic β-cells and impairment of their function in concert with the cytokine storm and counter-regulatory hormonal responses, new-onset diabetes besides severe metabolic complications of preexisting diabetes, including diabetic ketoacidosis and hyperosmolarity could set in patients with COVID-19 ( Aloysius et al, 2020 ; Ren et al, 2020 ; Rubino et al, 2020 ). On the other hand, worse consequences are observed in COVID-19 patients presented with diabetes, bracketed together with a range of associated conditions augmenting the risk ( Apicella et al, 2020 ).…”

Section: Resultsmentioning

confidence: 99%

Can CRISPR/Cas Technology Be a Felicitous Stratagem Against the COVID-19 Fiasco? Prospects and Hitches

Konwarh

2020

Front. Mol. Biosci.

View full text Add to dashboard Cite

The current global debacle of COVID-19, spelled by SARS-CoV-2 needs no elaboration. With incessant and constantly clambering number of deaths across various nations, the need of the hour is to develop readily deployable, fast, affordable detection assays and kits, yielding precise and consistent results as well as timely availability of efficacious anti-SARS-CoV-2 strategies to contain it. Conventionally employed real time PCR based technique for detection of the virus suffers from a couple of handicaps. Amongst other approaches, CRISPR based technology has ushered in new hopes. Recent efforts have been directed toward developing CRISPR/Cas based low-cost, rapid detection methods as well as development of one-pot assay platforms. The plausible application of CRISPR-Cas system to counteract the viral assault has also been assessed. The write up in this article mirrors the current status, the prospects and the practical snags of CRISPR/Cas technology for the detection and inactivation of the novel corona virus, SARS-CoV-2.

show abstract

Section: Resultsmentioning

confidence: 99%

Can CRISPR/Cas Technology Be a Felicitous Stratagem Against the COVID-19 Fiasco? Prospects and Hitches

Konwarh

2020

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…When looking at extra-vascular ndings, clinical events included ventilation-related complications like pneumothorax and pneumomediastinum only in a small proportion of ICU cases. Acute pancreatitis, that Aloysius et al have reported as COVID-19 presenting event [28], was also detected in 3 ICU cases thus allowing clinicians to start targeted therapies.…”

Section: Discussionmentioning

confidence: 98%

Lesson by SARS-Cov 2 disease (COVID-19): whole body CT angiography detection of relevant and other/incidental systemic vascular findings

Rea

Lassandro

Lieto

et al. 2020

Preprint

View full text Add to dashboard Cite

Objectives: The aim of our study was to assess the frequency distribution of relevant and incidental vascular events in a retrospective cohort of 42 COVID-19 patients. Methods: All patients were studied by whole-body CT angiography.Twenty-three out of 42 patients were admitted to the intensive care unit (ICU). Results: Relevant vascular events were recorded in the 71.4% of the whole study population. Pulmonary embolism was the most frequent one both in ICU and no-ICU cases (56.5% vs10.5%, p=0.002). Ischemic infarction of other organs was affecting with an increasing prevalence the gut, the spleen, the liver, the brain and the kidney, with a simultaneous ischemic occurrence in some cases. Multi-focal venous thrombosis was also represented especially in ICU patients (p=0.005). Among incidental findings, splanchnic vessels little-size aneurysms were reported in the 40% of the whole population, with relative frequencies similarly distributed in ICU and no-ICU patients.Conclusions: Vascular involvement is not negligible in COVID-19 and should be carefully investigated as may significantly affect disease behavior and prognosis.

show abstract

“…The most common symptoms in COVID-19 are fever and respiratory symptoms, followed by GI symptoms such as diarrhea, vomiting, anorexia, dysgeusia, and abdominal pain [ 4 , 56 - 59 ]. Based on the SECURE-IBD registry-based study, about 30% of the patients reported an increase in baseline IBD symptoms [ 55 ].…”

Section: Gi Manifestations Of Covid-19mentioning

confidence: 99%

Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned

Gajendran

Perisetti

Aziz

et al. 2020

aog

View full text Add to dashboard Cite

The current outbreak of COVID-19 pandemic caused by SARS-CoV-2 has affected nearly 188 countries. Patients with severe COVID-19 are more commonly elderly and suffer from comorbidities such as hypertension, diabetes mellitus, coronary artery disease, chronic pulmonary disease, obesity, and cancer. Inflammatory bowel disease (IBD) affects as many as 6.8 million people globally, and a significant proportion of them are treated with immunosuppressants. Hence, there is an ongoing concern over the impact of COVID-19 on IBD patients and their susceptibility to it. So far, there are about 1439 IBD patients in the Surveillance Epidemiology of Coronavirus under Research Exclusion (SECURE-IBD) registry reported to be infected with SARS-CoV-2. There are many unique challenges and dilemmas that need to be taken into account when managing an IBD patient with COVID-19. The management of each patient should be individualized. The IBD societies and experts have strongly recommended that patients should not discontinue their IBD medications. If the patients have symptoms of COVID-19 or IBD flare-up, they are recommended to call their IBD physician first to discuss their medication. In addition, IBD patients are urged to practice social distancing strictly to minimize the chances of infection. As COVID-19 is rapidly evolving, our experience and understanding of its impact on the IBD population may potentially change in the near future.

show abstract

COVID-19 presenting as acute pancreatitis

Cited by 181 publications

References 6 publications

Can CRISPR/Cas Technology Be a Felicitous Stratagem Against the COVID-19 Fiasco? Prospects and Hitches

Can CRISPR/Cas Technology Be a Felicitous Stratagem Against the COVID-19 Fiasco? Prospects and Hitches

Lesson by SARS-Cov 2 disease (COVID-19): whole body CT angiography detection of relevant and other/incidental systemic vascular findings

Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned

Contact Info

Product

Resources

About